Unexpected response to palliative radiotherapy for subcutaneous metastases of an advanced small cell pancreatic neuroendocrine carcinoma: a case report of two different radiation schedules.
Palliative radiotherapy
Pancreatic neuroendocrine carcinoma
Subcutaneous metastases
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
15 Apr 2020
15 Apr 2020
Historique:
received:
01
08
2019
accepted:
07
04
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
19
12
2020
Statut:
epublish
Résumé
Skin metastases from pancreatic neuroendocrine carcinoma (PNEC) are rare and their palliative treatment is challenging. We report our experience in the multimodal management of one of the few reported cases of metastatic PNEC with multiple visceral and subcutaneous secondary lesions, focusing on the effectiveness of palliative radiotherapy for skin metastases. A 61-years old woman affected by a metastatic PNEC - with subcutaneous growing and bleeding secondary lesions (at the scalp, right scapular region and at the back of the left thoracic wall, respectively) - obtained a successful control of visceral metastases with the use of chemotherapy and an unexpected local response of her skin metastases with palliative radiotherapy. In particular, two subsequent radiation treatments were performed using different fractionation schedules (30 Gy in 10 fractions and 20 Gy in 5 fractions, respectively). Both radiation treatments were well-tolerated and patient's quality of life was improved. Local response was maintained until patient's death - that occurred due to cachexia. The presented case highlights the effectiveness and the good tolerance of radiotherapy in the treatment of subcutaneous metastases; nevertheless, further knowledge of the optimal local palliative approach for PNEC metastatic sites is necessary. The experience gained in this work is the occasion to encourage a routine integrated multidisciplinary team management of metastatic PNECs because of their clinical complexity. The aim is to guarantee the optimization of the care with personalized and more effective systemic and local treatments - also including supportive cares and treatment-related side effects management.
Sections du résumé
BACKGROUND
BACKGROUND
Skin metastases from pancreatic neuroendocrine carcinoma (PNEC) are rare and their palliative treatment is challenging. We report our experience in the multimodal management of one of the few reported cases of metastatic PNEC with multiple visceral and subcutaneous secondary lesions, focusing on the effectiveness of palliative radiotherapy for skin metastases.
CASE PRESENTATION
METHODS
A 61-years old woman affected by a metastatic PNEC - with subcutaneous growing and bleeding secondary lesions (at the scalp, right scapular region and at the back of the left thoracic wall, respectively) - obtained a successful control of visceral metastases with the use of chemotherapy and an unexpected local response of her skin metastases with palliative radiotherapy. In particular, two subsequent radiation treatments were performed using different fractionation schedules (30 Gy in 10 fractions and 20 Gy in 5 fractions, respectively). Both radiation treatments were well-tolerated and patient's quality of life was improved. Local response was maintained until patient's death - that occurred due to cachexia.
CONCLUSIONS
CONCLUSIONS
The presented case highlights the effectiveness and the good tolerance of radiotherapy in the treatment of subcutaneous metastases; nevertheless, further knowledge of the optimal local palliative approach for PNEC metastatic sites is necessary. The experience gained in this work is the occasion to encourage a routine integrated multidisciplinary team management of metastatic PNECs because of their clinical complexity. The aim is to guarantee the optimization of the care with personalized and more effective systemic and local treatments - also including supportive cares and treatment-related side effects management.
Identifiants
pubmed: 32293342
doi: 10.1186/s12885-020-06845-x
pii: 10.1186/s12885-020-06845-x
pmc: PMC7161181
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
311Références
BMC Res Notes. 2015 Apr 11;8:139
pubmed: 25889083
Pol J Radiol. 2018 Feb 04;83:e63-e67
pubmed: 30038680
J Bras Pneumol. 2015 May-Jun;41(3):289-91
pubmed: 26176530
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
BMJ Case Rep. 2013 May 22;2013:
pubmed: 23704434
G Ital Dermatol Venereol. 2018 Oct;153(5):722-724
pubmed: 30246953
Curr Probl Cancer. 2018 Sep;42(5):527-533
pubmed: 29937242
World J Gastroenterol. 2015 Sep 7;21(33):9822-6
pubmed: 26361431
Case Rep Dermatol. 2015 Oct 02;7(3):263-74
pubmed: 26557073
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2701-6
pubmed: 24966991
West Indian Med J. 2014 Jul 3;63(6):667-72
pubmed: 25803388
Am J Dermatopathol. 2009 Apr;31(2):166-9
pubmed: 19318803
Neth J Med. 2002 Jun;60(5):207-11
pubmed: 12365476
Ann Dermatol. 2011 Sep;23 Suppl 1:S20-4
pubmed: 22028564
J Clin Oncol. 2014 Oct 1;32(28):3144-55
pubmed: 25154827
Cutis. 2017 May;99(5):E13-E15
pubmed: 28632813
Clin Oncol (R Coll Radiol). 2018 Jul;30(7):400-408
pubmed: 29615284
Dermatol Online J. 2017 Jan 15;23(1):
pubmed: 28329472
BMC Cancer. 2014 May 01;14:305
pubmed: 24884973
BMC Res Notes. 2014 Aug 08;7:505
pubmed: 25103825
Int Urol Nephrol. 2007;39(1):157-60
pubmed: 17268913
Medicine (Baltimore). 2018 Jan;97(2):e9415
pubmed: 29480829